TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Naltrexone (LDN) Immune Monitoring

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females age 18-65~* Meets criteria for 1990 ACR criteria for fibromyalgia~* Able to receive venous blood draw twice a week for 16 weeks~* Sufficient symptom variability during baseline report~* Patient completes daily report during 2 week baseline period at least 80% completion rate.~Exclusion Criteria:~* Opioid use~* Significant psychological comorbidity that in the discretion of the investigator compromises study integrity~* Location prohibits travel to Stanford~* Blood or clotting disorder~* Rheumatologic or autoimmune disease~* Acute infection~* Baseline blood ESR \>60, CRP greater than 3.0mg/L, positive rheumatoid factor, or positive ANA~* Use of blood thinning medication~* Pregnant or currently planning to become pregnant~* Current use of aspirin, ibuprofen, naproxen, or other confounding-anti-inflammatory medication as part of regular medication regimen.~* Known allergy to Naltrexone or Naloxone~* Currently participating in another treatment-based research study~* Self-reported inability to refrain from alcohol for the duration of the study period

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Low Dose Naltrexone (LDN) (Type: OTHER): Following a two-week baseline the study drug was administered daily for 8 weeks. Participants were informed that placebo or LDN would be provided during the drug period and that all participants would receive LDN at some point during the study. In fact, all participants received the active LDN (4.5 mg nocte) throughout the drug-administration period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Presence of a Companion During Performance of Neuraxial Labor Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Delivering the first child~* Planning to labor with neuraxial analgesia.~* Additionally, there will need to be sufficient time before delivery to allow the completion of the Pre procedure questionnaire, State-Trait Anxiety Inventory (STAI) questionnaire both before and after the procedure, as well as the Newest Vital Sign questionnaire and the Pain Catastrophizing Scale questionnaire before the procedure.~* They will be included if they are ASA (American Society of Anesthesiologists) 2.~* Able to read and comprehend the English language, as the Newest Vital Sign questionnaire requires them to read and interpret a nutrition label.~Physician Inclusion:~* Anesthesiology Attending Physician, fellow or resident who participants in the placement of the epidural catheter placement~Companion Inclusion:~* Primary companion identified by parturient over the age of 18~Exclusion Criteria:~* Parturients will be excluded if they are receiving neuraxial anesthesia for a cesarean delivery,~* External cephalic version~* Non-labor procedure.~* Subjects will be excluded if they begin to push for delivery before completion of the STAI questionnaire following labor epidural catheter placement.~* They will be excluded if there is no support person present at the time of the neuraxial procedure.~* They will be excluded if they are ASA 3 or greater, or if they have a contraindication to receiving any of the medications routinely used in the placement of a labor epidural catheter (lidocaine, bupivacaine, epinephrine, fentanyl).~* Adults who are unable to consent and minors will be excluded.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- No companion present (Type: NO_INTERVENTION): No companion is present during the placement of the epidural catheter.
- Companion present (Type: ACTIVE_COMPARATOR): A companion will be present during the placement of the epidural catheter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Long-term Treatment With TEZ/IVA in CF Participants With an F508del CFTR Mutation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed the Week 24 Visit in Study 113 Part B or the Week 8 Visit in Study 115~* Eligible CFTR Mutation~Exclusion Criteria:~* Pregnant and nursing females~* History of poor compliance with study drug and/or procedures in a previous study as deemed by the investigator~* Ongoing participation in another study with investigational drug~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TEZ/IVA (Type: EXPERIMENTAL): Part A: Participants weighing less than (\<)40 kilograms (kg) at Day 1 received tezacaftor (TEZ) 50 milligrams (mg) once daily (qd)/ivacaftor (IVA) 75 mg every 12 hours (q12h) and the participants weighing greater than or equals to (\>=) 40 kg at Day 1 received TEZ 100 mg qd/IVA 150 mg q12h in the treatment period for 96 weeks. Doses were adjusted upward for changes in body weight and/or age.~Part B: Participants weighing \<30 kg at Day 1 received TEZ 50 mg qd/IVA 75 mg q12h and the participants weighing \>=30 kg at Day 1 received TEZ 100 mg qd/IVA 150 mg q12h in the treatment period up to 192 weeks. Doses were adjusted upward for changes in body weight and/or age.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients must meet DSM-IV criteria for Major Depressive Disorder.~* Patients must have severe depression.~* MADRS greater than or equal to 30~Exclusion Criteria:~* Women who are pregnant, women who will be breastfeeding during the study, and women of childbearing potential who are not practicing a reliable method of birth control.~* Patients who are considered a suicide risk.~* Patients who currently meet DSM-IV criteria for: a principal diagnosis for Axis I disorder other than MDD (comorbid GAD is allowed), bipolar disorder, schizophrenia or any psychotic disorder, obsessive-compulsive disorder, dysthymia.~* Patients with a family history of bipolar disorder, schizophrenia, or any psychotic disorder.~* Patients with history of any psychotic disorder or any psychotic feature.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Metformin Effects on Oxidative Stress Parameters in Newly Diagnosed Type 2 Diabetes Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed type 2 diabetes patients based on American Diabetes Association criteria for diagnosis of diabetes~Exclusion Criteria:~* No history of serious chronic illnesses of heart, lung, and kidney~* No prior treatment with anti-diabetes medications for either diabetes or conditions associated with hyperglycemia~* No intake of prescribed or over-the-counter vitamins C and E in the past year; - No intake of aspirin in the past year~* No history of excessive alcohol intake in the past year

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Case (Type: ACTIVE_COMPARATOR): Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
- Control (Type: NO_INTERVENTION): Subjects provided only advice for lifestyle modification with no drug intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine Infusion for Treatment-resistant Major Depressive Disorder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Outpatients with severe treatment-resistant MDD~* Currently depressed~* Currently under regular psychiatric care~* On an aggressive antidepressant regimen, stable for 4 weeks~Exclusion Criteria:~* No history of other major psychiatric illnesses, including bipolar disorder~* No history of psychosis~* No history of drug abuse~* No major medical illness or unstable medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Ketamine IV (Type: EXPERIMENTAL): Patients will receive open label augmentation with IV Ketamine at 0.5mg/kg, twice a week for 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2a Study of VX-147 in Adults With APOL1-mediated Focal Segmental Glomerulosclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* APOL1 genotype of G1/G1, G2/G2, or G1/G2~* FSGS diagnosed by kidney biopsy~Key Exclusion Criteria:~* Evidence of non-APOL1-mediated FSGS~* Participants with known sickle cell disease~* Solid organ or Bone marrow transplant~Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VX-147 (Type: EXPERIMENTAL): All participants received VX-147 at a dosage of 15 mg once daily (qd) for 2 weeks and VX-147 at a dosage of 45 mg qd for 11 weeks. Part A was enrolled in 2 cohorts: Cohort 1 and Cohort 2. Cohort 1 included participants with urine protein to creatinine ratio (UPCR) approximately greater than or equal to (≥) 3 g/g (± 10%) and less than (\<) 10 g/g and estimated glomerular filtration rate (eGFR) approximately ≥30 mL/min/1.73 m2 (± 10%). Cohort 2 included participants with UPCR approximately ≥0.8 g/g (± 10%) and \<2.7 g/g and eGFR approximately ≥30 mL/min/1.73 m2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with T2DM not on an AHA or on any AHA in monotherapy or combination therapy (including oral or non oral agents)~* Patients with reduced kidney function~Exclusion Criteria:~* History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or beta cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy~* Have proliferative diabetic retinopathy for which treatment is planned during the course of the study~* Kidney disease that required treatment with immunosuppressive therapy, history of dialysis or kidney transplant, presence of nephrotic syndrome (eg, severe proteinuria with hypoalbuminemia and/or edema), or inflammatory kidney disease~* Receiving anti hypertensive or anti-hyperlipidemic therapy not on a stable regimen~* History of a severe hypoglycemic episode within 6 months before screening

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each patient will receive 100 mg of canagliflozin once daily for 52 weeks.
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each patient will receive 300 mg of canagliflozin once daily for 52 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Each patient will receive matching placebo once daily for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test 2 Doses of the HRV Vaccine in Healthy Infants.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~* Healthy infants 6-13 weeks of age at the time of the first study vaccination whose parent/guardian sign a written informed consent and whose parents/guardians can and will comply with the requirements of the protocol (e.g., completion of the diary cards, return for follow-up visits)~Exclusion criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccine(s) within 30 days preceding the first dose of study vaccine or placebo, or planned use during the study period~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth. (Topical steroids are allowed.)~* Child is unlikely to remain in the study area for the duration of the study~* Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection~* History of allergic disease or reaction likely to be exacerbated by any component of the vaccine~* Administration of immunoglobulins and/or blood products since birth or planned administration during the study period~* Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract or other serious medical condition as determined by the investigator

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 13 Weeks
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intervention to Improve Care at Life's End

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Aim 1: Not applicable. Patients were deceased.~* Aim 2: After-death interviews with next of kin: must be willing and able to participate in after-death interview at local VA Medical Center.~Exclusion Criteria:~* N/A

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Ablation Versus antiaRrhythmic Drugs in Persistent Atrial Fibrillation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with persistent atrial fibrillation (more than 7 days, or less than 7 days needing pharmacologic or electric cardioversion)~Exclusion Criteria:~* Hypo or hyperthyroidism~* Persistent atrial fibrillation lasting more than 1 year or non-defined duration~* Hypertrophic myocardiopathy~* Implantable defibrillation or pacemaker implanted~* Moderate or severe mitral valve disease or mitral prosthetic valve~* Ejection fraction less than 30%~* Left atrial anteroposterior diameter more than 50 mm.~* Previous atrial fibrillation ablation~* Contraindication to anticoagulation~* Left atrium thrombus~* Current infective disease or sepsis~* Pregnant women~* Current unstable angor~* Acute myocardial infarction in last 3 months~* Atrial fibrillation secondary to ionic disturbance, thyroids disease or secondary to any other reversible or non cardiovascular disease~* Reduced expectancy of life (less than 12 months)~* Patient participating in another clinical study that investigates a drug or device~* Psychologically unstable patient or denies to give informed consent~* Any cause that contraindicate ablation procedure or antiarrhythmic drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Atrial Fibrillation Ablation (Type: EXPERIMENTAL): None
- Drug therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than 44 weeks beyond neonatal period but less than 12 months~* Presumptive diagnosis of GERD~* Weight greater than 2.5 kg but less than 15 kg~Exclusion Criteria:~* History of gastrointestinal (GI) disorders, ie, unrepaired tracheal esophageal fistula, GI malabsorption~* Clinically significant medical or surgical abnormalities

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 11 Months
- Healthy Volunteers: f

Study Arms:
- Low dose (Type: ACTIVE_COMPARATOR): None
- High dose (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Paliperidone Extended Release (ER) Among Thai Schizophrenia Participants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) criteria for schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self)~* Participants unsatisfied with their previous treatment~* Previously or currently on oral atypical antipsychotics~Exclusion Criteria:~* Serious unstable medical condition, including recent and present clinically relevant laboratory abnormalities~* History or current symptoms of tardive dyskinesia (twitching or jerking movements that you cannot control in your face, tongue, or other parts of your body)~* History of neuroleptic malignant syndrome (high fever, rigid muscles, shaking, confusion, sweating more than usual, increased heart rate or blood pressure, or muscle pain or weakness)~* Pregnant or breast-feeding female~* Participation in an investigational drug trial within 30 days prior to selection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paliperidone Extended Release (ER) (Type: EXPERIMENTAL): Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chiropractic Care, Medication, and Self-Care for Neck Pain

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Exclusion Criteria:~* Pregnant women, due to use of diagnostic procedures (x-rays) and study treatments (NSAIDs and narcotic medications)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Medical history of Heart Failure (HF) with at least 1 prior hospitalization for HF or clinical evidence of HF (without hospitalization) manifested by signs or symptoms of volume overload or elevated intracardiac pressures (e.g., elevated jugular venous pressure, shortness of breath or signs of pulmonary congestion on x-ray or auscultation, peripheral edema) that required/requires treatment with a diuretic for improvement,~* Evidence of cardiac involvement by echocardiography with an end-diastolic interventricular septal wall thickness \> 12 mm,~* Presence of amyloid deposits in biopsy tissue and presence of a variant TTR genotype and/or TTR precursor protein identification by immunohistochemistry, scintigraphy or mass spectrometry~Exclusion Criteria:~* A New York Heart Association (NYHA) classification of IV.~* Presence of primary (light chain) amyloidosis.~* Prior liver or heart transplantation or implanted cardiac mechanical assist device.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Tafamidis - 20 mg (Type: EXPERIMENTAL): Active Treatment-Low dose
- Tafamidis - 80 mg (Type: EXPERIMENTAL): Active Treatment-High Dose
- Placebo (Type: PLACEBO_COMPARATOR): Placebo control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete